The continuous selection pressure subsequently exerted by TKI therapy might select for mutations conferring TKI resistance under a situation where enhanced STAT5 levels and activity promotes survival in a subset of CML clones. Here, STAT5B is linked to chronic myelogenous leukemia, BCR-ABL1 positive.